The genotype data could be used to identify individuals and so cannot be made openly available. Access to data is open through collaboration. Requests for collaboration will be considered following an application to the Genetic Beta Cell Research Bank (<https://www.diabetesgenes.org/current-research/genetic-beta-cell-research-bank/>). Contact by email should be directed to the Lead Nurse, Dr Bridget Knight (<b.a.knight@exeter.ac.uk>).

Introduction {#sec001}
============

Congenital hyperinsulinism (CHI), a disorder of heterogeneous aetiology characterised by dysregulated and inappropriate insulin secretion, is a significant cause of hypoglycaemia in neonates and infants with the potential for permanent neurologic injury. CHI can be transient or persistent. Transient CHI is usually associated with stress in the antenatal or perinatal period, such as intrauterine growth restriction or birth asphyxia, and typically resolves in the first few months of life, the majority by 6 months of age \[[@pone.0228417.ref001], [@pone.0228417.ref002], [@pone.0228417.ref003]\]. Individuals with persistent CHI continue to require medical therapy or surgery to stabilise blood glucose levels and up to 50--65% of patients in this group are without an identified mutation in any of the known CHI genes \[[@pone.0228417.ref004], [@pone.0228417.ref005]\]. Previous estimates of the incidence of CHI in outbred populations have ranged from 1 in 27,000 in Ireland to 1 in 50,000 in the Netherlands \[[@pone.0228417.ref006], [@pone.0228417.ref007]\]. The precise criteria for defining CHI however has varied between studies, at times have been unclear and has often not distinguished between transient and persistent forms \[[@pone.0228417.ref008], [@pone.0228417.ref009], [@pone.0228417.ref005]\]. Moreover, the incidence of CHI within the UK has yet to be determined. As accurate estimates are needed for both health care provision and research purposes, we have now calculated the minimal incidence of CHI within the UK based on referral rates to a central diagnostic genetic testing laboratory.

Materials and methods {#sec002}
=====================

This study was approved by the North Wales Research Ethics Committee (517/WA/0327). Consent was not obtained as the data were analysed anonymously. The incidence of CHI for a region can be calculated from referral rates to a diagnostic laboratory and the annual birth rate. As not all cases will necessarily be referred for testing, this will reflect a minimum incidence for the region. The Exeter Molecular Genetics Laboratory, at the Royal Devon and Exeter Hospital (Exeter, UK) is the sole centre for clinical genetic testing for CHI in the UK. As the clinical care for patients with CHI in the UK is largely provided through two nationally commissioned, National Health Service-funded centres, the referral rate for genetic testing for this condition is high.

To calculate the minimal incidence of CHI over a 10-year period we identified all referrals for genetic testing for CHI from England, Wales, Scotland and Northern Ireland from 2007 to 2016. CHI was defined as having an inappropriate insulin and C-peptide measurement during hypoglycaemia in the clinical context of recurrent hypoglycaemia and high glucose infusion rate suggestive of hyperinsulinism \[[@pone.0228417.ref010], [@pone.0228417.ref011]\] diagnosed within the first 12 months of life. Although both insulin and C-peptide were measured, insulin was used as the primary biomarker with C-peptide as a supporting adjunct. All cases had laboratory glucose levels \<3 mmol/L with a concurrent, unequivocally raised insulin level. Inclusion criteria were persistence of CHI beyond 6 months or requirement for pancreatectomy to manage hypoglycaemia. Persistence of CHI was defined as continuing need for medical therapy and/or dietary carbohydrate supplementation to prevent hypoglycaemia. The cut-off of 6 months was used to exclude cases of transient CHI, associated with environmental factors around the perinatal period, as most transient cases resolve within 6 months \[[@pone.0228417.ref001], [@pone.0228417.ref002], [@pone.0228417.ref003]\]. Data on the duration and management of CHI, including requirement for surgery, was obtained from the genetic testing request form. If this information was not provided at the time of testing, the referring physician was contacted to provide these details. Data on live births from 2007 to 2016 was obtained from the Office of National Statistics (<https://www.ons.gov.uk/peoplepopulationandcommunity>, accessed 27/07/19), National Records of Scotland (<https://www.nrscotland.gov.uk/statistics-and-data/statistics>, accessed 27/07/19) and the Northern Ireland Statistics and Research Agency (<https://www.nisra.gov.uk/publications/birth-statistics>, accessed 24/08/19). There were a total of 7,892,004 live births in the United Kingdom from 2007 to 2016 inclusive: 7,069,592 in England and Wales; 574,601 in Scotland and 247,811 in Northern Ireland. 95% Confidence intervals were calculated for the study population and the estimates from other countries where data were available for calculation ([S1 Table](#pone.0228417.s001){ref-type="supplementary-material"}).

Results {#sec003}
=======

Between 2007 to 2016, 278 UK patients (55% male) referred for genetic testing had biochemically-confirmed CHI persisting for more than 6 months or had undergone pancreatic surgery for CHI (74/278, 27%) ([Fig 1](#pone.0228417.g001){ref-type="fig"}). Median glucose was 1.8 mmol/L (interquartile range (IQR) 1.3, 2.3) with insulin 90 pmol/L (median; IQR 44,168) and C-peptide 700 pmol/L (median; IQR 374, 1224). CHI persisted beyond 12 months in 229 of these cases (82%). Consanguinity was reported in 24/278 patients (8.6%). Disease-causing variants in known CHI genes were identified in 154 (55%) individuals, of which mutations in the potassium ATP channel genes *ABCC8* and *KCNJ11* were the most common (115/154, 74%). The pick-up rate for disease-causing variants in patients with reported consanguinity was 16/24 (67%). The mutation detection rate in the cohort is similar to previous reports \[[@pone.0228417.ref002], [@pone.0228417.ref005], [@pone.0228417.ref004]\]. Using these data and dividing by the number of live births from 2007 to 2016 for England, Scotland, Wales and Northern Ireland, which was 7,892,004, the minimum annual incidence of CHI in the UK was calculated as 1 in 28,389 live births (95% CI 1:25 000, 1:32 258) ([Fig 2](#pone.0228417.g002){ref-type="fig"}). This decreases to 1 in 34,463 for those with CHI at 12 months of age or older. Where a disease-causing variant was identified, the incidence was 1 in 51,247 for those with CHI at 6 months of age and 1 in 54,806 for those with CHI at 12 months.

![Flow diagram showing the outcomes of referrals for genetic testing for congenital hyperinsulinism.](pone.0228417.g001){#pone.0228417.g001}

![The incidence of congenital hyperinsulinism in the UK compared to other outbred populations.\
In the current study, CHI was diagnosed based on a non-suppressed insulin and C-peptide level at the time of hypoglycaemia with persistence beyond 6 months of age or need for pancreatectomy. Incidence is expressed as the number per 100,000 live births with the 95% confidence intervals (CI) provided with each estimate where calculated. The 95% CI could not be calculated for Ireland or Japan as the estimates were based on unpublished or unavailable data, respectively.](pone.0228417.g002){#pone.0228417.g002}

Discussion {#sec004}
==========

We have calculated an incidence of 1 case of CHI per 28,389 live births in the UK from 2007 to 2016. This estimate is similar to that previously reported for Ireland (1 in 27,000) but higher than estimates for other outbred populations ([Fig 2](#pone.0228417.g002){ref-type="fig"}) \[[@pone.0228417.ref006], [@pone.0228417.ref007], [@pone.0228417.ref008], [@pone.0228417.ref009], [@pone.0228417.ref005]\]. Although this could reflect a true increase in incidence, given the overlapping or near-overlapping 95% CI compared to estimates from other countries, the difference is more likely due to the small sample sizes in other studies ([S1 Table](#pone.0228417.s001){ref-type="supplementary-material"}). Regardless, this study provides an accurate estimate on the minimal incidence of CHI in the UK, which was previously unknown.

A greater incidence of CHI could be due to a number of factors. Improved awareness of CHI and a better understanding of the genetic aetiologies over the last decades is likely to have resulted in an increase in detection and reporting of CHI cases. We did not detect an overall trend of increasing incidence from 2007--2016 ([S2 Table](#pone.0228417.s002){ref-type="supplementary-material"}), however the increase in numbers may well have occurred prior to this time period. Differences in inclusion criteria may have also contributed with some studies using higher insulin thresholds, possibly due to differences in assay sensitivity, and this could have resulted in underdetection of CHI \[[@pone.0228417.ref009]\].

Furthermore, although most cases of transient CHI resolve by 6 months of age, our cohort may have included transient cases that had not yet resolved. However, given that 83% of cases continued to persist at 12 months of age ([Fig 1](#pone.0228417.g001){ref-type="fig"}), this is unlikely to have played a significant role. In our cohort, consanguinity was reported in 24 individuals; the pick-up rate for mutations within this group was high (16/24, 67%) in keeping with the autosomal recessive nature of the most common genetic aetiologies. This high prevalence of recessive genetic disease in CHI can explain the much higher incidence rates of CHI in consanguineous populations: 1 in 2,675 in Saudi Arabia and 1 in 19,960 in Kuwait \[[@pone.0228417.ref012], [@pone.0228417.ref013]\].

The major limitation of this study is that it is derived from a single centre to which referrals for genetic testing were voluntary. However, as CHI in the UK is managed by a highly-specialised service funded on a national level, most cases of CHI in which genetic testing would have been clinically indicated (i.e. severity, persistence of disease or features suggesting a genetic aetiology) would have been referred to the Exeter laboratory for testing. Moreover, as genetic testing is government-funded it is unlikely that patients would have been tested outside of the UK.

The criteria for CHI diagnosis was a non-suppressed insulin and/or C-peptide level at the time of hypoglycaemia. While the measurement of C-peptide may not be specific to the diagnosis of CHI, its use as an adjunct with serum insulin in the context of robust supportive clinical criteria is reasonably justified and is unlikely to over-represent the reported incidence of CHI. A further limitation of our study is that we were unable to determine persistence of CHI in 104 patients. Given that these patients were lost to follow-up, it seems most likely that the CHI was transient and would therefore be unlikely to affect the calculated incidence of persistent CHI. Our calculation thus reflects the minimal incidence of CHI in the UK. It is important to note that transient cases can be severe despite the self-resolving nature and have been reported to be more common than persistent forms, consistent with the association with perinatal stress \[[@pone.0228417.ref009]\]. Transient CHI therefore deserves further study to establish its incidence and natural history.

Ensuring accurate calculations of the incidence of disease has important implications for both health care and medical research. The clinical management of CHI, particularly persistent forms, can be complex, requiring input from endocrinology, specialised nuclear medicine imaging, surgical expertise, allied health professionals and clinical laboratories \[[@pone.0228417.ref011]\]. Accurate incidence data are therefore important for health services planning. As well, hypoglycaemia can be due to causes other than CHI, and it is important to understand the incidence of CHI relative to other aetiologies. Furthermore, as genetic sequencing technologies have become more widely used both as clinical and research tools, rare genetic variants are increasingly identified which are often difficult to classify. One widely used approach to help determine likely pathogenicity is to assess how frequently the variant appears in large population databases such as the Genome Aggregation Database (gnomAD) \[[@pone.0228417.ref014], [@pone.0228417.ref015]\]. The success of this approach however relies on accurate calculations of the incidence disease within the population.

In conclusion we have shown that the incidence of CHI in the UK is at least 1 in 28,389 live births. Current incidence estimates are imperative for both health care planning and accurate interpretation of the results of genetic testing, which will help advance our understanding of CHI.

Supporting information {#sec005}
======================

###### Data used for CHI incidence and 95% CI calculation in other outbred study populations.

(DOCX)

###### 

Click here for additional data file.

###### Incidence of CHI in the UK by year from 2007 to 2016.

The cases of CHI had either persisted beyond 6 months of age or required pancreatectomy for hypoglycaemia.

(DOCX)

###### 

Click here for additional data file.
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3\. Have the authors made all data underlying the findings in their manuscript fully available?
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Reviewer \#1: This is an interesting study of clinical importance, however with some epidemiological flaws.

1\. In the methods, it is not clear how the clinical data were obtained. Did you have access to hospital file data or were the data based on questionnaires in the genetic testing request form? Genetic testing usually takes place prior to surgery. How did you obtain the surgery data? How did you know what age the patients had when determining persistence \> 6 or 12 months?

2\. Methods: An "or" diagnostic criteria of elevated C-peptide is doubtful, as the prolonged half-life of C-peptide compared to insulin implies that p-C-peptide does not reflect rapid changes in p-glucose. Indeed, the two references mentioned (Stanley, Banerjee) did not use elevated C-peptide as a diagnostic criteria. However, the inclusion criteria were sound (\>6 mo CHI or surgery). However, it is very unlikely that an infant with an erroneous diagnosis of CHI based on C-peptide would be subjected to pancreatectomy or would still require therapy after 6 mo. The diagnostic problem on C-peptide should be mentioned in Limitations.

3\. In Results, the only included patients had CHI persisting \> 6 months' age. Did no patient undergo pancreatic surgery \<6 months' age? And if they did, did you miss to detect them?

4\. Why are the p-glucose, p-insulin and C-peptide data not presented? Is the study based on genetic testing requests only without actual data on the diagnosis? If the diagnoses were not actually validated it would be fair to state.

5\. A patient inclusion flow chart is missing. The 104 patients lost to follow-up should be presented in a Results flow chart Figure 1. Why was it not possible in a country like the UK to perform a follow-up on these children?

6\. An incidence calculation is always an estimate of the true, unknown incidence. Although many publications on incidences do not deal with details, a report on incidence only definitely should. For epidemiologists, a 95% confidence interval would be a demand. Your sampling is large enough to give a narrower C.I. than most others in the field. If you compute 95% C.I.s on the other incidences reported from other countries, one would better understand whether differences are significant or due to small samples.

7\. Moreover, your data set is large enough to dive a little into time trends and geographical distribution. Did the incidence increase with time? This would suggest more referrals rather than a true increase. Were some geographic areas underrepresented? If yes, why?

8\. In Discussion, the calculation is presented as a minimal incidence, as probably, or almost, all UK patients had genetic testing done in Exeter. Is it possible that some persistent CHI patients did not undergo genetic testing at all, perhaps especially in the beginning of the period studied?
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The authors present a interesting study but some areas needs attention. Please, respond to th questions raised by reviewer 1. Indeed, the questions around the use of C-peptide as a diagnostic criteria is relevant and presentation of the actual measurements including p-insulin and p-glucose would be of great value.

Thank you for your reply regarding our manuscript, "Using referral rates for genetic testing to determine the incidence of a rare disease: the minimal incidence of congenital hyperinsulinism in the UK is 1 in 28,389". We have addressed the points raised during the review process and enclose a point-by-point response as well as revised manuscript. We hope these changes are found to be satisfactory.

Reviewer \#1: This is an interesting study of clinical importance, however with some epidemiological flaws.

1\. In the methods, it is not clear how the clinical data were obtained. Did you have access to hospital file data or were the data based on questionnaires in the genetic testing request form? Genetic testing usually takes place prior to surgery. How did you obtain the surgery data? How did you know what age the patients had when determining persistence \> 6 or 12 months?

We thank the Reviewer for their positive and constructive comments. The clinical data were obtained from the genetic testing request form, which encompassed details regarding hyperinsulinism treatment including surgery. If the outcome was unknown, the requesting clinician was contacted to provide data regarding persistence at 6 and 12 months of age, and treatment including surgery. We have revised the manuscript to reflect this.

2\. Methods: An "or" diagnostic criteria of elevated C-peptide is doubtful, as the prolonged half-life of C-peptide compared to insulin implies that p-C-peptide does not reflect rapid changes in p-glucose. Indeed, the two references mentioned (Stanley, Banerjee) did not use elevated C-peptide as a diagnostic criteria. However, the inclusion criteria were sound (\>6 mo CHI or surgery). However, it is very unlikely that an infant with an erroneous diagnosis of CHI based on C-peptide would be subjected to pancreatectomy or would still require therapy after 6 mo. The diagnostic problem on C-peptide should be mentioned in Limitations.

We acknowledge the Reviewer's point regarding the use of C-peptide in diagnosing hyperinsulinism. We used C-peptide as an additional biomarker in the context of recurrent, severe hypoglycaemia and high glucose infusion rates consistent with hyperinsulinism causing hypoglycaemia while recognizing the importance of insulin as a prime diagnostic marker. We have revised the manuscript to reflect the Reviewer's comments.

3\. In Results, the only included patients had CHI persisting \> 6 months' age. Did no patient undergo pancreatic surgery \<6 months' age? And if they did, did you miss to detect them?

We thank the Reviewer for clarifying this. The patients undergoing surgery were included in N=278 patients. We apologise for not having made this clearer and have amended the manuscript to indicate the number of patients undergoing pancreatic surgery.

4\. Why are the p-glucose, p-insulin and C-peptide data not presented? Is the study based on genetic testing requests only without actual data on the diagnosis? If the diagnoses were not actually validated it would be fair to state.

The genetic testing request form included data on glucose, insulin and c-peptide to confirm evidence of CHI prior to genetic testing. We have now included these values in the results of the manuscript.

5\. A patient inclusion flow chart is missing. The 104 patients lost to follow-up should be presented in a Results flow chart Figure 1. Why was it not possible in a country like the UK to perform a follow-up on these children?

A patient inclusion flow chart was provided as a supplemental figure. We have now provided this as figure 1 and the incidence data as figure 2. For the 104 patients lost to follow up, we had contacted the referring physicians to obtain outcome data, but either the patient was no longer in the physician's care or were lost to their follow up, or we did not receive a reply despite several attempts.

6\. An incidence calculation is always an estimate of the true, unknown incidence. Although many publications on incidences do not deal with details, a report on incidence only definitely should. For epidemiologists, a 95% confidence interval would be a demand. Your sampling is large enough to give a narrower C.I. than most others in the field. If you compute 95% C.I.s on the other incidences reported from other countries, one would better understand whether differences are significant or due to small samples.

We have now calculated 95% confidence intervals for our data set as well as for the incidences reported from other countries. These are included these in figure 2 and the data used for calculation in supporting table S1. However, we were unable to calculate 95% CI for the incidences for Ireland and Japan. The former is based on unpublished data and the latter is published in Japanese. Overall, the estimates from the outbred populations are overlapping or nearly overlapping, in the case of the Czech Republic estimate. It therefore appears the differences are due to small sample sizes in the other populations versus a significant differences between the populations. We have revised our discussion to reflect this analysis.

7\. Moreover, your data set is large enough to dive a little into time trends and geographical distribution. Did the incidence increase with time? This would suggest more referrals rather than a true increase. Were some geographic areas underrepresented? If yes, why?

As the reviewer has suggested, we have examined the incidence over time (S2 table). Although the annual incidence fluctuated year by year, a sustained increase was not observed over the time period studied. We have not examined the incidence by geography as we do not have data on the location of birth, only location of treatment. It would not be accurate to include data on treatment location given that there are two tertiary referral centres to which patients are referred from all over the UK.

8\. In Discussion, the calculation is presented as a minimal incidence, as probably, or almost, all UK patients had genetic testing done in Exeter. Is it possible that some persistent CHI patients did not undergo genetic testing at all, perhaps especially in the beginning of the period studied?

We anticipate most if not all patients undergoing genetic testing for CHI in the UK would have been referred to Exeter. However, it is possible, as the reviewer states, that some patients with CHI may not have undergone testing at all, particularly if the hypoglycaemia could be managed with diazoxide.

Reviewer \#2: This is a well designed and conducted epidemiological study that is presented in a clearly and concisely. The methods and interpretation of data are appropriate. The limitations noted are comprehensive and reasonable. While this is not a landmark study, it does add valuable incidence information that will be useful for planning and operationalizing treatment of a condition that affects a very small population.

We kindly thank the Reviewer for their positive comments regarding our study.
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